Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir plus atazanavir dosing schedule crossover study in chronic HIV infection
ACTRN12609000179235Phase 4Completed
- Sponsor
- The Kirby Institute
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of raltegravir, atazanavir and ritonavir in human immunodeficiency virus infection (HIV), sponsored by The Kirby Institute. Started Apr 2009; status: completed.
02
Drugs
raltegraviratazanavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ACTRN12609000179235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000179235.